[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100515842":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":18,"locations":10,"responsibleParty":24,"collaborators":10,"id":28,"slug":29,"hasResults":30,"nctId":31,"briefTitle":32,"officialTitle":32,"acronym":10,"eligibilityCriteria":33,"healthyVolunteers":30,"sex":34,"minAge":35,"maxAge":10,"enrollmentInfo":36,"targetDuration":10,"studyType":39,"phases":10,"briefSummary":40,"conditions":41,"keywords":45,"overallStatus":48,"whyStopped":10,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":10},{"fullName":5,"class":6},"Qianfoshan Hospital","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"Patients with COVID-19 packaged with Paxlovid",null,"Treatment of patients with COVID-19 with Paxlovid",{"label":13,"type":10,"description":14,"interventionNames":10},"Patients with COVID-19 packaged with Azvudine","Treatment of patients with COVID-19 with Azvudine",{"label":16,"type":10,"description":17,"interventionNames":10},"Patients with COVID-19 packaged with Paxlovid and Azvudine","Treatment of patients with COVID-19 with Paxlovid and Azvudine",[19],{"name":20,"role":21,"phone":22,"phoneExt":10,"email":23},"Xiao Li","CONTACT","18210590697","lixiao1688@163.com",{"type":25,"investigatorFullName":26,"investigatorTitle":27,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Xiao Li，MD","Associate professor of pharmacy","100515842","evaluation-of-the-safety-and-efficacy-of-azvudine-and-paxlovid-in-the-treatment-of-hospitalized-patients-with-covid-19-100515842",false,"NCT05996770","Evaluation of the Safety and Efficacy of Azvudine and Paxlovid in the Treatment of Hospitalized Patients With COVID-19","Inclusion Criteria:\n\n* 1\\. The patient's admission time is from December 1,2022 to January 31,2023. 2. The patient has used either Paxlovid or azivudine tablets during admission. 3. Age ≥ 18 years old. Exclusion Criteria：\n* 1\\. Patients using other antiviral drugs. 2. Patients with incomplete clinical data.","ALL","18 Years",{"count":37,"type":38},1500,"ESTIMATED","OBSERVATIONAL","In this retrospective study, we aimed to evaluate the clinical efficacy and safety of two antiviral drugs on COVID-19 and inpatients with existing complications in the First Affiliated Hospital of Shandong First Medical University. In addition, we also explored a key issue. Is the combined treatment effect of two antiviral drugs, Paxlovid and Azvudine, better than the use of a single drug?",[42,43,44],"Paxlovid","Azvudine","COVID-19",[42,43,44,46,47],"effectiveness","real-world evidence","UNKNOWN","2024-04-02",{"date":51,"type":52},"2024-04-03","ACTUAL",{"date":54,"type":38},"2024-06-01",{"date":56,"type":38},"2024-12-30",{"name":26,"class":6}]